Sinovac Biotech Ltd.’s coronavirus vaccine in Brazil and Turkey suggesting the shot has a protection rate on either side of 90%, there is still no final assessment on exactly how effective it is in protecting people against Covid-19.Sinovac is finalizing results of phase III trials carried out in Brazil, Turkey, Indonesia and Chile, according to a person familiar with the trials.
Those tests are relatively independent from each other and conducted according to different protocols, rather than subject to unified norms that typically govern such trials, said the person, who asked not to be identified because the data isn’t public.Also Read | The global drive to reimagine capitalismResearchers in Brazil earlier this week delayed releasing.